2 profitable ex-penny shares to consider for an ISA

Our writer highlights two small caps that were penny shares not too long ago. Both are posting rising profits and look set for further growth.

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Most penny shares have a poor financial outlook. However, there are gems, including this pair of small caps that were in penny stock territory this time last year. Both are doing incredibly well lately as the market starts to reward their financial progress.

I reckon they’re worthy of attention for stock-pickers looking to add smaller growth companies to their ISA portfolios. Here’s why.


First up is Renold (LSE: RNO). The stock has more than doubled over the past year and is now priced at 59p, giving the firm a market cap of £134m.

Renold is a global supplier of industrial chains and power transmission products. Its chains are known for their reliability and are used in industries such as manufacturing, mining, and agriculture.

The company has also made bespoke chains for the Great Britain Cycling Team’s track cyclists since 2011 — a period of great success. Beyond chains, it manufactures gearboxes and couplings.

Results for the year ended 31 March 2024 were “materially ahead” of previous expectations (the full-year report is due on 17 July). Revenue was expected to increase just 0.9% year on year to £241.5m (at constant exchange rates), but adjusted operating profits were approximately 20% higher.

The group said its productivity and efficiency programmes were driving sustainable profit margin improvement. And at £83.6m, the order book was at near-record levels.

Meanwhile, it has made over 100 bespoke chains for the British Olympic and Paralympic teams in Paris this summer. And it recently won a contract from the Royal Canadian Navy worth £10.6m.

Now, one issue is that Renold has some debt on its balance sheet following acquisitions, which adds risk. But I’m encouraged to see that its net debt position had been reduced by £4.9m to £24.9m at the end of March.

Overall, this small-cap stock is worth considering, in my opinion. The forward price-to-earnings (P/E) ratio is just 8.8. That’s really low for a firm with great momentum and whose profit margins are expanding.


Next up we have hVIVO (LSE: HVO), which I hold shares in. At 28p, the stock is up around 84% over the past year, giving a market cap of £190m.

The company specialises in human challenge clinical trials. These are where healthy volunteers are exposed to pathogens (like viruses) in a controlled environment to test vaccine efficacy. It recruits these volunteers through its dedicated FluCamp service.

Running these trials is a lucrative little niche, as we can see by the firm’s 35% compound annual growth rate in revenue between 2018 and 2023. Net profit last year was £16.1m on revenue of £56m.

It has also just moved into a new, state-of-the-art facility in Canary Wharf. This houses the world’s largest human challenge trial unit and is expected to help hVIVO grow its annual revenue to £100m by 2028.

One risk here is that the company doesn’t have a long track record of profitability. A return to losses would hurt the stock quite badly, I fear.

Still, the firm remains confident in its prospects and has even started paying a dividend. And it’s just won its largest field study contract to date (for a phase 2b influenza drug candidate).

The future looks very bright. I’m considering buying more shares.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in hVIVO Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

How to start earning passive income for life with just £3.40 a day

Dividends can be a tremendous and lucrative source of passive income, even when only investing a tiny sum each day.…

Read more »

Investing Articles

2 bargain FTSE 100 shares with dividend yields above 9%!

These FTSE 100 stocks look cheap, based on predicted earnings and dividends. Here's why I think they could be great…

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

2 top growth shares I’d buy for the second half of 2024!

Looking for the best growth shares to buy? These FTSE 250 and small-cap shares have significant share price potential, according…

Read more »

Investing For Beginners

How to try and build a £250k Stocks and Shares ISA from scratch, starting in 2024

With a regular savings plan and a smart investment strategy, it’s possible to build wealth within a Stocks and Shares…

Read more »

Investing Articles

I’m considering 3 top UK dividend stocks for my portfolio this July

Mark David Hartley is looking at adding a few dividend stocks to his portfolio this month. Will these three shares…

Read more »

Investing Articles

3 FTSE 100 shares I’d buy to create lasting passive income

Dividend stocks are a great way to build an additional income. Our writer details three FTSE 100 picks she’d love…

Read more »

Investing Articles

After falling 9% in 6 weeks, is this FTSE 100 stock now in bargain territory?

The BAE Systems share price hit a 52-week high on 3 June. Six weeks later, it’s down nearly 10%. Is…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

I love the look of Entain shares, potentially 47% undervalued

Many FTSE 100 companies have been on a tear in 2024, but with Entain shares down nearly 50%, I think…

Read more »